ROSGQ (Rosetta Genomics) Dividend Payout Ratio: 0.00 (As of Jun. 2017)


What is Rosetta Genomics Dividend Payout Ratio?

Rosetta Genomics ROSGQ -99.00% Dividend Payout Ratio is 0.00 as of Jun. 2017.

The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. Rosetta Genomics's Dividend Payout Ratio for the months ended in Jun. 2017 was 0.00.

The historical rank and industry rank for Rosetta Genomics's Dividend Payout Ratio or its related term are showing as below:


ROSGQ's Dividend Payout Ratio is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 0.49
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2026-06-28), the Dividend Yield % of Rosetta Genomics is 0.00%.

Rosetta Genomics's Dividends per Share for the months ended in Jun. 2017 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.


Rosetta Genomics (OTCPK:ROSGQ) Dividend Payout Ratio Explanation

In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.


Rosetta Genomics Dividend Payout Ratio Related Terms


Rosetta Genomics Dividend Payout Ratio Historical Data

* Premium members only.

The historical data trend for Rosetta Genomics's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rosetta Genomics Dividend Payout Ratio Chart

Rosetta Genomics Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Dividend Payout Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Rosetta Genomics Semi-Annual Data
Dec07 Jun08 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17
Dividend Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ROSGQ vs TEAR, IDTA, ABMC: Dividend Payout Ratio Comparison

For the Diagnostics & Research subindustry, Rosetta Genomics's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rosetta Genomics Dividend Payout Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Rosetta Genomics's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Rosetta Genomics's Dividend Payout Ratio falls into.



Rosetta Genomics Dividend Payout Ratio Calculation

The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.

Rosetta Genomics's Dividend Payout Ratio for the fiscal year that ended in Dec. 2016 is calculated as

Dividend Payout Ratio=Dividends per Share (A: Dec. 2016 )/ EPS without NRI (A: Dec. 2016 )
=0/ -9.303
=N/A

Rosetta Genomics's Dividend Payout Ratio for the quarter that ended in Jun. 2017 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Jun. 2017 )/ EPS without NRI (Q: Jun. 2017 )
=0/ -1.31
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Dividend Payout Ratio →
What does a Dividend Payout Ratio of 0.00 mean?
Rosetta Genomics (ROSGQ) has a Dividend Payout Ratio of 0.00 as of Jun. 2017. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Rosetta Genomics and its competitors.
Is Rosetta Genomics' Dividend Payout Ratio too high?
Rosetta Genomics' current Dividend Payout Ratio is 0.00.
How does Rosetta Genomics' Dividend Payout Ratio compare to TEAR and IDTA?
Rosetta Genomics' Dividend Payout Ratio of 0.00 can be compared against companies in the Medical Diagnostics & Research industry. The industry median Dividend Payout Ratio is 0.49. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Payout Ratio for a Medical Diagnostics & Research company?
The median Dividend Payout Ratio among Medical Diagnostics & Research companies is 0.49, based on 55 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Payout Ratio significantly above this median, while those in the bottom quartile fall well below. However, Dividend Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Payout Ratio mean?
A high Dividend Payout Ratio can signal that a stock is expensive relative to its fundamentals. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Rosetta Genomics and its competitors. For the Medical Diagnostics & Research industry, the median Dividend Payout Ratio is 0.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rosetta Genomics's current Dividend Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rosetta Genomics stock overvalued right now?
Rosetta Genomics (ROSGQ) has a current Dividend Payout Ratio of 0.00. The current Dividend Payout Ratio is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Payout Ratio calculated?
Dividend Payout Ratio is calculated from a company's financial statements. For Rosetta Genomics (ROSGQ), the current Dividend Payout Ratio is 0.00 as of Jun. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rosetta Genomics Business Description

Address 10 Plaut Street, Science Park, Rehovot, ISR, 76706
Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.